Onconetix Stock Performance
| ONCO Stock | USD 0.61 0.08 11.59% |
The company holds a Beta of 1.29, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Onconetix will likely underperform. At this point, Onconetix has a negative expected return of -2.47%. Please make sure to check Onconetix's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Onconetix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Onconetix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:40 | Last Split Date 2024-09-24 |
1 | Acquisition by Meier Thomas of 3318 shares of Onconetix subject to Rule 16b-3 | 09/26/2024 |
2 | Whats Going On With Onconetix Shares Friday | 09/27/2024 |
3 | Insider Trading | 11/01/2024 |
| Begin Period Cash Flow | 25.8 M | |
| Free Cash Flow | -13.6 M |
Onconetix |
Onconetix Relative Risk vs. Return Landscape
If you would invest 508.00 in Onconetix on September 5, 2024 and sell it today you would lose (447.00) from holding Onconetix or give up 87.99% of portfolio value over 90 days. Onconetix is currently does not generate positive expected returns and assumes 14.0731% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Onconetix, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Onconetix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Onconetix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Onconetix, and traders can use it to determine the average amount a Onconetix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1752
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ONCO |
Estimated Market Risk
| 14.07 actual daily | 96 96% of assets are less volatile |
Expected Return
| -2.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Onconetix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Onconetix by adding Onconetix to a well-diversified portfolio.
Onconetix Fundamentals Growth
Onconetix Stock prices reflect investors' perceptions of the future prospects and financial health of Onconetix, and Onconetix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Onconetix Stock performance.
| Return On Equity | -17.58 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (3.00) % | ||||
| Current Valuation | 19.42 M | ||||
| Shares Outstanding | 8.29 M | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 3.47 X | ||||
| Revenue | 58.47 K | ||||
| EBITDA | (36.71 M) | ||||
| Net Income | (37.41 M) | ||||
| Cash And Equivalents | 113.36 K | ||||
| Cash Per Share | 0.85 X | ||||
| Total Debt | 9.89 M | ||||
| Current Ratio | 0.62 X | ||||
| Book Value Per Share | (64.14) X | ||||
| Cash Flow From Operations | (13.58 M) | ||||
| Earnings Per Share | (109.20) X | ||||
| Market Capitalization | 5.08 M | ||||
| Total Asset | 87.52 M | ||||
| Retained Earnings | (56.79 M) | ||||
| Working Capital | (11.35 M) | ||||
About Onconetix Performance
By examining Onconetix's fundamental ratios, stakeholders can obtain critical insights into Onconetix's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Onconetix is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 100.87 | 95.82 | |
| Return On Tangible Assets | (5.82) | (5.53) | |
| Return On Capital Employed | (0.51) | (0.54) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.64) | (0.67) |
Things to note about Onconetix performance evaluation
Checking the ongoing alerts about Onconetix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Onconetix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Onconetix generated a negative expected return over the last 90 days | |
| Onconetix has high historical volatility and very poor performance | |
| Onconetix has some characteristics of a very speculative penny stock | |
| Onconetix has a very high chance of going through financial distress in the upcoming years | |
| Onconetix was previously known as BWV and was traded on NASDAQ Exchange under the symbol BWV. | |
| Onconetix currently holds 9.89 M in liabilities. Onconetix has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Onconetix's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 58.47 K. Net Loss for the year was (37.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Onconetix currently holds about 113.36 K in cash with (13.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Onconetix has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Insider Trading |
- Analyzing Onconetix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Onconetix's stock is overvalued or undervalued compared to its peers.
- Examining Onconetix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Onconetix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Onconetix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Onconetix's stock. These opinions can provide insight into Onconetix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.